Dr. Wanlapa Roobsoong leads groundbreaking research on the molecular mechanisms underlying gametocytogenesis and hypnozoite formation in Plasmodium vivax. Her work focuses on addressing critical challenges in malaria control, such as parasite dormancy, relapse, and transmission. Dr. Roobsoong integrates cutting-edge technologies into her research, including humanized mouse models, induced pluripotent stem (iPS) cells, and organ-on-chip systems representing liver, bone marrow, and spleen, to unravel the complexities of P. vivax biology and accelerate the discovery of new antimalarial drugs and vaccines.

Dr. Roobsoong has extensive experience in the radical cure treatment of P. vivax, focusing on improving the efficacy and safety of therapeutic interventions. She has led initiatives such as mass primaquine preventive treatment programs at the population level, providing critical insights into the practical implementation of radical cure strategies. Her current work includes clinical studies on dose optimization of tafenoquine, aiming to refine treatment regimens and address challenges associated with relapsing infections. While G6PD deficiency remains an area of interest, it serves as a supporting aspect of her broader focus on P. vivax radical cure treatments.

Through her innovative research and collaborative approach, Dr. Roobsoong continues to shape the global understanding of P. vivax and contribute to the Mahidol Vivax Research Unit's mission of eliminating malaria and improving global health